Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Dec;19(12):1773-1780.
doi: 10.1111/dom.13026. Epub 2017 Jul 25.

Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting

David Russell-Jones  1 , Simon R Heller  2 , Sarah Buchs  3 , Anna Sandberg  3 , William J Valentine  4 , Barnaby Hunt  4
Affiliations
Randomized Controlled Trial

Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting

David Russell-Jones et al. Diabetes Obes Metab. 2017 Dec.

Abstract

Aim: To assess the impact of faster aspart vs insulin aspart on long-term clinical outcomes and costs for patients with type 1 diabetes mellitus (T1DM) in the UK setting.

Methods: The QuintilesIMS CORE Diabetes Model was used to project clinical outcomes and costs over patient lifetimes in a cohort with data on baseline characteristics from the "onset 1" trial. Treatment effects were taken from the 26-week main phase of the onset 1 trial, with costs and utilities based on literature review. Future costs and clinical benefits were discounted at 3.5% annually.

Results: Projections indicated that faster aspart was associated with improved discounted quality-adjusted life expectancy (by 0.13 quality-adjusted life-years) vs insulin aspart. Improved clinical outcomes resulted from fewer diabetes-related complications and a delayed time to their onset with faster aspart. Faster aspart was found to be associated with reduced costs vs insulin aspart (cost savings of £1715), resulting from diabetes-related complications avoided and reduced treatment costs.

Conclusions: Faster aspart was associated with improved clinical outcomes and cost savings vs insulin aspart for patients with T1DM in the UK setting.

Keywords: cost-effectiveness; insulin therapy; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

B. H. and W. J. V. are employees of Ossian Health Economics and Communications. Ossian received funding from Novo Nordisk A/S to perform the present analysis. S. B. was an employee of Novo Nordisk when this research was conducted. A. S. is an employee of Novo Nordisk A/S. D. R.‐J. has received research funding, advisory panel fees and lecture panel honoraria from Astra Zenica, Boehringer Ingelheim, Cellnovo, Lilly, Novartis, Novo Nordisk, and Sanofi. S. R. H. has received personal fees from Sanofi Aventis, Eli Lilly, Takeda, Novo Nordisk and Astra Zeneca for serving on Speaker panels, and is an employee of the University of Sheffield, which has received remuneration from Eli Lilly, Boeringher Ingelheim, Novo Nordisk, and Takeda for consultancy.

Figures

Figure 1
Figure 1
Cumulative incidence and mean time to onset of diabetes‐related complications over patient lifetimes.
Figure 2
Figure 2
Direct costs over patient lifetimes with faster aspart and insulin aspart and cost savings with faster aspart as a result of avoided diabetes‐related complications. £, 2015 pounds sterling
See this image and copyright information in PMC

References

    1. National Institute for Health and Care Excellence . NG17: Type 1 diabetes in adults: diagnosis and management. 2015. Available at: http://www.nice.org.uk/guidance/ng17. Accessed November 1, 2016. - PubMed
    1. National Institute for Health and Care Excellence . NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management. 2015. Available at: http://www.nice.org.uk/guidance/ng18. Accessed November 1, 2016. - PubMed
    1. National Diabetes Audit 2011–2012. Report 2: Complications and Mortality. 2013. Available at: http://www.hscic.gov.uk/catalogue/PUB12738/nati‐diab‐audi‐11‐12‐mort‐com.... Accessed November 1, 2016.
    1. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–862. - PubMed
    1. The DCCT Research Group , Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. - PubMed

Publication types

MeSH terms